These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21083052)

  • 21. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry.
    Hopfgartner G; Bourgogne E
    Mass Spectrom Rev; 2003; 22(3):195-214. PubMed ID: 12838545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micro LC/MS in drug analysis and metabolism studies.
    Henion J; Skrabalak D; Dewey E; Maylin G
    Drug Metab Rev; 1983; 14(5):961-1003. PubMed ID: 6360611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel MS solutions inspired by MIST.
    Ramanathan R; Josephs JL; Jemal M; Arnold M; Humphreys WG
    Bioanalysis; 2010 Jul; 2(7):1291-313. PubMed ID: 21083241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in bioanalytical LC-MS using the Orbitrap™ mass analyzer.
    Scigelova M; Makarov A
    Bioanalysis; 2009 Jul; 1(4):741-54. PubMed ID: 21083136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applications of accelerator MS in pediatric drug evaluation.
    Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
    Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples.
    Jemal M; Ouyang Z; Powell ML
    Rapid Commun Mass Spectrom; 2002; 16(16):1538-47. PubMed ID: 12203245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix effect elimination during LC-MS/MS bioanalytical method development.
    Côté C; Bergeron A; Mess JN; Furtado M; Garofolo F
    Bioanalysis; 2009 Oct; 1(7):1243-57. PubMed ID: 21083049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
    Gu H; Wang J; Aubry AF; Jiang H; Zeng J; Easter J; Wang JS; Dockens R; Bifano M; Burrell R; Arnold ME
    Anal Chem; 2012 Jun; 84(11):4844-50. PubMed ID: 22540405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity-based analytical approaches to support human absolute bioavailability studies.
    Xu XS; Jiang H; Christopher LJ; Shen JX; Zeng J; Arnold ME
    Bioanalysis; 2014 Feb; 6(4):497-504. PubMed ID: 24568352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parallel extraction columns and parallel analytical columns coupled with liquid chromatography/tandem mass spectrometry for on-line simultaneous quantification of a drug candidate and its six metabolites in dog plasma.
    Xia YQ; Hop CE; Liu DQ; Vincent SH; Chiu SH
    Rapid Commun Mass Spectrom; 2001; 15(22):2135-44. PubMed ID: 11746878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument.
    Li AC; Alton D; Bryant MS; Shou WZ
    Rapid Commun Mass Spectrom; 2005; 19(14):1943-50. PubMed ID: 15954168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of HILIC-MS in quantitative bioanalysis of drugs and drug metabolites.
    Hsieh Y
    J Sep Sci; 2008 May; 31(9):1481-91. PubMed ID: 18428187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.